GSK announces a $2.5 billion cost-savings program aimed at funding research and development. The company positions the initiative as part of efforts to accelerate its drug pipeline, according to multiple reports. The plan is presented as a way to free up resources for R&D activities, including clinical development work.
Quartz adds additional context from GSK’s recent quarterly results, saying the company beats second-quarter profit expectations. Quartz also reports that, following the results, GSK expects to begin 20 or more Phase III clinical trials in 2026. Together, the coverage links the savings program to a pipeline timeline that includes a larger late-stage development schedule.
Across the sources, the main points are that GSK launches a $2.5 billion savings drive and ties it to increased investment in its drug pipeline. The reports do not provide further operational details, such as specific measures or where the cuts occur, but they consistently describe the savings figure and the R&D purpose. The company’s outlook for Phase III trial starts in 2026 is highlighted by Quartz.
